{"id":"NCT00007020","sponsor":"Mirum Pharmaceuticals, Inc.","briefTitle":"Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid","officialTitle":"Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1992-01","primaryCompletion":"2009-12","completion":"2009-12","firstPosted":"2000-12-07","resultsPosted":"2020-07-15","lastUpdate":"2023-10-03"},"enrollment":85,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Infantile Refsum's Disease","Zellweger Syndrome","Adrenoleukodystrophy","Peroxisomal Disorders","Cholestasis"],"interventions":[{"type":"DRUG","name":"Cholic Acids","otherNames":["Cholic","Cholic Acid","Cholic Acid Capsules"]}],"arms":[{"label":"Cholic Acid","type":"OTHER"}],"summary":"OBJECTIVES:\n\nI. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism\n\nII. To assess the safety and tolerability of cholic acid","primaryOutcome":{"measure":"Number of Participants With Excretion of Atypical Bile Acids in Urine by Category","timeFrame":"Baseline, then every 1, 3, or 6 months (depending on protocol version) for an average of 2.8 years","effectByArm":[{"arm":"Cholic Acid","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["28644367"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":79},"commonTop":["Pyrexia","Upper respiratory tract infection","Fracture","Convulsion","Diarrhoea"]}}